PRODUCT INFORMATION



BMS-3

Item No. 19421

CAS Registry No.:	1338247-30-5	, H
Formal Name:	N-[5-[1-(2,6-dichlorophenyl)-3-	
	(difluoromethyl)-1H-pyrazol-5-yl]-2-	
	thiazolyl]-cyclopropanecarboxamide	
MF:	$C_{17}H_{12}CI_{2}F_{2}N_{4}OS$	
FW:	429.3	
Purity:	≥95%	
UV/Vis.:	λ _{max} : 299 nm	Ń ĆI
Supplied as:	A crystalline solid	
Storage:	-20°C	F
Stability:	≥2 years	۴

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BMS-3 is supplied as a crystalline solid. A stock solution may be made by dissolving the BMS-3 in the solvent of choice. BMS-3 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of BMS-3 in these solvents is approximately 1, 25, and 15 mg/ml, respectively.

BMS-3 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BMS-3 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. BMS-3 has a solubility of approximately 0.2 mg/ml in a 1:5 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

BMS-3 is a potent inhibitor of activated LIM domain kinases LIMK1 and LIMK2 (IC₅₀s = 5 and 6 nM, respectively).¹ It is used to study the role of activated LIMK isoforms in the signaling of Rho family GTPases to cytoskeletal proteins, including cofilin and tubulin.²⁻⁴

References

- 1. Ross-Macdonald, P., de Silva, H., Guo, Q., et al. Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol. Cancer Ther. 7(11), 3490-3498 (2008).
- Li, X., Zhu, Y., Cao, Y., et al. LIM kinase activity is required for microtubule organising centre positioning 2. in mouse oocyte meiosis. Reprod. Fertil. Dev. (2016).
- Romarowski, A., Battistone, M.A., La Spina, F.A., et al. PKA-dependent phosphorylation of LIMK1 and 3. Cofilin is essential for mouse sperm acrosomal exocytosis. Dev. Biol. 405(2), 237-249 (2015).
- 4. Sari-Hassoun, M., Clement, M.-J., Hamdi, I., et al. Cucurbitacin I elicits the formation of actin/phosphomyosin II co-aggregates by stimulation of the RhoA/ROCK pathway and inhibition of LIM-kinase. Biochem. Pharmacol. 102, 45-63 (2016).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/03/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM